Photocure ASA

Remuneration Information • Mar 26, 2025

Photocure ASA - Share option grant to Vice President and General Manager EMEA

Photocure ASA - Share option grant to Vice President and General Manager EMEA

Oslo, Norway, 26 March 2025 - Photocure ASA (the "Company") (OSE: PHO) has

granted share options to Jane Healy, the Company's newly appointed Vice

President and General Manager EMEA as announced separately by the Company today.

A total of 100,000 share options have been issued to Jane Healy at an exercise

price of NOK 57.59. The exercise price is equal to the weighted average share

price 30 trading days before day of grant with an additional premium of 10% on

top of the calculated average price.

The options are granted in accordance with the Company's long term incentive

program and the Company's guidelines for remuneration of senior executives (the

"Guidelines"), as approved by the annual general meeting of the Company held 23

May 2024. The share option program and properties of the options are further

described in the Guidelines.

A primary insider notification pursuant to the market abuse regulation article

19 is attached.

For further information, please contact:

Dan Schneider

President and CEO

Photocure ASA

Email: ds@photocure.com

Erik Dahl

CFO

Photocure ASA

Tel: +4745055000

Email: ed@photocure.com

Media and IR enquiries:

Geir Bjørlo

Corporate Communications (Norway)

Tel: +47 91540000

Email: geir.bjorlo@corpcom.no

Note to editors:

All trademarks mentioned in this release are protected by law and are registered

trademarks of Photocure ASA.

This press release may contain product details and information which are not

valid, or a product is not accessible, in your country. Please be aware that

Photocure does not take any responsibility for accessing such information which

may not comply with any legal process, regulation, registration or usage in the

country of your origin.

About Bladder Cancer

Bladder cancer ranks as the 8th most common cancer worldwide - the 5th most

common in men - with 1949000 prevalent cases (5-year prevalence rate)1a, 614000

new cases and more than 220000 deaths in 2022.1b

Approx. 75% of all bladder cancer cases occur in men.1 It has a high recurrence

rate with up to 61% in year one and up to 78% over five years.2 Bladder cancer

has the highest lifetime treatment costs per patient of all cancers.3

Bladder cancer is a costly, potentially progressive disease for which patients

have to undergo multiple cystoscopies due to the high risk of recurrence. There

is an urgent need to improve both the diagnosis and the management of bladder

cancer for the benefit of patients and healthcare systems alike.

Bladder cancer is classified into two types, non-muscle invasive bladder cancer

(NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of

invasion in the bladder wall. NMIBC remains in the inner layer of cells lining

the bladder. These cancers are the most common (75%) of all BC cases and include

the subtypes Ta, carcinoma in situ (CIS) and T1 lesions. In MIBC the cancer has

grown into deeper layers of the bladder wall. These cancers, including subtypes

T2, T3 and T4, are more likely to spread and are harder to treat.4

1 Globocan. a) 5-year prevalence / b) incidence/mortality by population.

Available at: https://gco.iarc.fr/today, accessed [February 2024].

2 Babjuk M, et al. Eur Urol. 2019; 76(5): 639-657

3 Sievert KD et al. World J Urol 2009;27:295-300

4 Bladder Cancer. American Cancer Society. https://www.cancer.org/cancer/bladder

-cancer.html

About Hexvix®/Cysview® (hexaminolevulinate HCl)

Hexvix/Cysview is a drug that preferentially accumulates in cancer cells in the

bladder, making them glow bright pink during Blue Light Cystoscopy (BLC®). BLC

with Hexvix/Cysview, compared to standard white light cystoscopy alone, improves

the detection of tumors and leads to more complete resection, fewer residual

tumors, and better management decisions.

Cysview is the tradename in the U.S. and Canada, Hexvix is the tradename in all

other markets. Photocure is commercializing Cysview/Hexvix directly in the U.S.

and Europe and has strategic partnerships for the commercialization of

Hexvix/Cysview in China, Chile, Australia, New Zealand and Israel. Please refer

to https://photocure.com/partners/our-partners for further information on our

commercial partners.

About Photocure ASA

Photocure: The Bladder Cancer Company delivers transformative solutions to

improve the lives of bladder cancer patients. Our unique technology, making

cancer cells glow bright pink, has led to better health outcomes for patients

worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo

Stock Exchange (OSE: PHO). For more information, please visit us at

www.photocure.com/news

This information is subject to the disclosure requirements pursuant to the

market abuse regulation article 19 and 5-12 of the Norwegian Securities Trading

Act.